Story perspectives

BeOne Medicines Promotes Wang Lai to Co-President Role

12/19/2025

Summary

Story summary

BeOne Medicines appointed Wang Lai, BeOne's global head of R&D since April 2021, as co-president, effective January, expanding his duties to include business development and managing alliances.
The board approved Wang Lai's promotion on December 17.
BeOne's leadership will be Wang Lai, a United States citizen and Joyant Pharmaceuticals leader, and Wu Xiaobin, a German citizen and former Pfizer executive who holds co-president title, a change that supports BeOne's pipeline.

1 of 1

Story summary

BeOne Medicines appointed Wang Lai, BeOne's global head of R&D since April 2021, as co-president, effective January, expanding his duties to include business development and managing alliances.
The board approved Wang Lai's promotion on December 17.
BeOne's leadership will be Wang Lai, a United States citizen and Joyant Pharmaceuticals leader, and Wu Xiaobin, a German citizen and former Pfizer executive who holds co-president title, a change that supports BeOne's pipeline.